Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV

Blood (2014) 124 (21): 3138.

https://doi.org/10.1182/blood.V124.21.3138.3138

Published: 2014

Journal Articles

Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy

Blood (2012) 120 (21): 3761.

https://doi.org/10.1182/blood.V120.21.3761.3761

Published: 2012

Journal Articles

Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT

Patrice Chevallier, Myriam Labopin, MD, MS, Stefanie Buchholz, Arnold Ganser, MD, Fabio Ciceri, MD, Bruno Lioure, Christoph Faul, MD, Gaelle Guillerm, Juergen Finke, MD, Anne Huynh, MD, Joerg Schubert, MD, Hans Jochem Kolb, MD, Emmanuelle Polge, Arnon Nagler, M.D., Mohamad Mohty, MD, PhD

Blood (2011) 118 (21): 3004.

https://doi.org/10.1182/blood.V118.21.3004.3004

Published: 2011

Journal Articles

Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial

Blood (2011) 118 (21): 332.

https://doi.org/10.1182/blood.V118.21.332.332

Published: 2011

Journal Articles

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Blood (2010) 116 (21): 40.

https://doi.org/10.1182/blood.V116.21.40.40

Published: 2010

Journal Articles

Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Robert A Brodsky, MD, Carlos de Castro, III, MD, Hubert Schrezenmeier, MD, Professor, Antonio M. Risitano, MD, PhD, Joerg Schubert, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Ulrich Duehrsen, MD, Lucio Luzzatto, MD, FRCP, FRCPath, Petra Muus, MD, PhD, Jeffrey Szer, BMedSc, MBBS, FRACP, Gérard Socié, MD, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 4237.

https://doi.org/10.1182/blood.V116.21.4237.4237

Published: 2010

Journal Articles

Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma

Blood (2010) 116 (21): 2396.

https://doi.org/10.1182/blood.V116.21.2396.2396

Published: 2010

Journal Articles

Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL).

Michael Pfreundschuh, Niels Murawski, Samira Zeynalova, Viola Poeschel, Marcel Reiser, Anthony D. Ho, Christina Nickenig, Swen Wessendorf, Bernd Metzner, Sandra Grass, Joerg Schubert, Markus Loeffler, Norbert Schmitz

Blood (2009) 114 (22): 3715.

https://doi.org/10.1182/blood.V114.22.3715.3715

Published: 2009

Journal Articles

MERIT Study – “Multicenter Evaluation of Patient- and Lesion-Specific Prognostic Factors for RadioImmunoTherapy with 90 yttrium-Labeled Anti-CD20 in Follicular Non-Hodgkin's lymphoma”.

Aleksandar Grgic, MD, Ursula Nestle, MD, PhD, Elena Ballek, MD, Klemens Scheidhauer, MD, PhD, Cornelia Puskas, MD, Jochem Koenig, PhD, Karin Hohloch, MD, Joerg Schubert, MD, Lorenz H. Truemper, Carl-Martin Kirsch, MD, PhD

Blood (2009) 114 (22): 4792.

https://doi.org/10.1182/blood.V114.22.4792.4792

Published: 2009

Journal Articles

Effects of Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Concurrent Immunosuppressive Therapy for Bone Marrow Insufficiency.

Hubert Schrezenmeier, Joerg Schubert, MD, Lucio Luzzatto, MD, Petra Muus, MD, PhD, Gerard Socie, MD, PhD, Antonio M. Risitano, MD, PhD, Anita Hill, MBChB, (Hons), PhD, Peter Hillmen, MB, ChB, PhD

Blood (2009) 114 (22): 3012.

https://doi.org/10.1182/blood.V114.22.3012.3012

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Bertram Glass, MD, PhD, Justin Hasenkamp, MD, Anke Goerlitz, Peter Dreger, Joerg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, Lorenz H. Truemper, MD, Norbert Schmitz

Blood (2009) 114 (22): 3379.

https://doi.org/10.1182/blood.V114.22.3379.3379

Published: 2009

Journal Articles

Effect of Reducing Intravascular Hemolysis on Ferritin Homeostasis in Eculizumab Treated Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients.

Alexander Roeth, MD, Joerg Schubert, MD, Christina Hock, Sandra Christoph, Ulrich Duehrsen, MD

Blood (2008) 112 (11): 3437.

https://doi.org/10.1182/blood.V112.11.3437.3437

Published: 2008

Journal Articles

Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment

Richard Kelly, MD, Louise Arnold, BSc, MA, Stephen J. Richards, PhD, Anita Hill, MD, Charlotte Bomken, MD, John Hanley, MD, Andrew Loughney, MD, PhD, Gus Khursigara, PhD, Russell P. Rother, PhD, Elizabeth Chalmers, MD, Edward Fitzsimons, MD, Ryotaro Nakamura, MD, Anna Gaya, MD, Bruno Rotoli, MD, Antonio M. Risitano, MD, PhD, Joerg Schubert, MD, Peter Hillmen, MB, PhD

Blood (2008) 112 (11): 4576.

https://doi.org/10.1182/blood.V112.11.4576.4576

Published: 2008

Journal Articles

Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)

Peter Dreger, MD, Stephan Stilgenbauer, MD, PhD, Sebastian Boettcher, MD, Matthias Ritgen, Sascha Dietrich, Donald Bunjes, MD, Dietrich Wilhelm Beelen, MD, Sandra Cohen, MD, FRCP(C), Ute Hegenbart, Joerg Schubert, MD, Michael Stadler, MD, Bertram Glass, MD, PhD, Andreas Burchert, MD, Lutz Uharek, Michael Hallek, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner

Blood (2008) 112 (11): 565.

https://doi.org/10.1182/blood.V112.11.565.565

Published: 2008

Journal Articles

Identification of New Minor Histocompatibility Antigens (mHags) in Patients with Chronic Graft Versus Host Disease (GvH) after Allogeneic Stem Cell Transplantation by SEREX.

Joerg Thomas Bittenbring, Manfred Ahlgrimm, Markus Ditschkowski, Frank Neumann, Joerg Schubert, Klaus-Dieter Preuss, Dietrich Wilhelm Beelen, MD, Michael Pfreundschuh

Blood (2008) 112 (11): 2198.

https://doi.org/10.1182/blood.V112.11.2198.2198

Published: 2008

Journal Articles

The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin- Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL

Michael Pfreundschuh, MD, Marita Ziepert, Marcel Reiser, Viola Poeschel, Sibylla Wilhelm, Tobias Gaska, Michael Heike, Norbert Schmitz, Christian Ruebe, Markus Loeffler, Joerg Schubert

Blood (2008) 112 (11): 584.

https://doi.org/10.1182/blood.V112.11.584.584

Published: 2008

Journal Articles

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Bertram Glass, MD, Justin Hasenkamp, MD, Peter Dreger, MD, Martin Gramatzki, MD, Joerg Schubert, MD, Gerald G. Wulf, MD, Maike Nickelsen, MD, Lorenz H. Truemper, MD, Norbert Schmitz, MD

Blood (2007) 110 (11): 3043.

https://doi.org/10.1182/blood.V110.11.3043.3043

Published: 2007

Journal Articles

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Christoph Schmid, MD, Johanna Tischer, MD, Matthias Stelljes, MD, Michael Schleuning, MD, Rainer Schwerdtfeger, MD, Ute Hegenbart, MD, Joerg Schubert, MD, Wichard Vogel, MD, Berd Gruhn, MD, Christiane Lallinger, Georg Ledderose, MD, Martin Bornhaeuser, MD, Joachim Kienast, MD, Hans-Jochem Kolb, MD

Blood (2007) 110 (11): 1651.

https://doi.org/10.1182/blood.V110.11.1651.1651

Published: 2007

Journal Articles

A Phase I/II Dose Escalation Trial of ONCOHIST® (Recombinant Human Histone H1.3) in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Michael Zeppezauer, Grazina Formicka-Zeppezauer, MD, Peter Gross, MD, Hans Joernvall, Joerg Schubert, Michael Pfreundschuh

Blood (2007) 110 (11): 918.

https://doi.org/10.1182/blood.V110.11.918.918

Published: 2007

Journal Articles

Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Blood (2007) 110 (11): 788.

https://doi.org/10.1182/blood.V110.11.788.788

Published: 2007

NARROW

A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV

Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy

Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT

Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma

Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL).

MERIT Study – “Multicenter Evaluation of Patient- and Lesion-Specific Prognostic Factors for RadioImmunoTherapy with 90 yttrium-Labeled Anti-CD20 in Follicular Non-Hodgkin's lymphoma”.

Effects of Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Concurrent Immunosuppressive Therapy for Bone Marrow Insufficiency.

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Effect of Reducing Intravascular Hemolysis on Ferritin Homeostasis in Eculizumab Treated Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients.

Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment

Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)

Identification of New Minor Histocompatibility Antigens (mHags) in Patients with Chronic Graft Versus Host Disease (GvH) after Allogeneic Stem Cell Transplantation by SEREX.

The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin- Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

A Phase I/II Dose Escalation Trial of ONCOHIST® (Recombinant Human Histone H1.3) in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only